Find uplifting stories about heroes, innovations, and solutions
9 results for "multiple myeloma"
A blood cancer treatment that works like a "Trojan horse" to destroy cells from within just received approval in New Zealand, offering hope to 2,500 patients with multiple myeloma. One patient who joined the trial says the drug gave her confidence to believe in her future again.
A breakthrough immune therapy is transforming multiple myeloma from a disease that always returned into one where patients can reach long-term remission. More than 36,000 Americans diagnosed this year now have access to treatments once considered impossible.
After beating multiple myeloma twice through clinical trials, Julie Cohen turned her battle into a mission. She now dedicates her life to coaching other cancer patients through their darkest moments.
A newly approved combination therapy is giving people with hard-to-treat multiple myeloma real hope, with over 80% of patients still alive three years after treatment. The FDA greenlit the two-injection approach after seeing results that far outpaced standard treatments.
A groundbreaking combination therapy for multiple myeloma just won FDA approval, nearly tripling survival rates compared to standard treatment. This could become the new standard of care for thousands of cancer patients facing relapse.
A groundbreaking clinical trial shows 83% of multiple myeloma patients remained cancer-free for three years using a two-drug immunotherapy combination. The FDA fast-tracked approval in just four months, offering real hope that this once-incurable cancer may now be curable for most patients.
Scientists discovered how cancer cells hide from cutting-edge immunotherapy and used an existing drug to make the treatment work again. Six patients whose immune cell therapy had stopped working saw their cancer respond once more.
Cancer patients fighting multiple myeloma can now skip painful bone marrow tests thanks to a breakthrough blood test available at 7,000 locations nationwide. The affordable new test detects lingering cancer cells just as accurately while costing far less than existing options.
Cancer patients with multiple myeloma can now track their treatment progress with a simple blood draw instead of painful bone marrow biopsies. This breakthrough makes monitoring minimal residual disease faster, easier, and less painful for thousands of patients.